CORRECTION: Moonshot Client Axolotl Announces Merger with Carmell Therapeutics; Axolotl's Shareholders To Receive $65M In CTCX Stock Upon Closing; Gain Up To $75M In Potential Milestone Equity Payments
Portfolio Pulse from Bill Haddad
Axolotl, a client of Moonshot, has announced a merger with Carmell Therapeutics. Upon closing, Axolotl's shareholders will receive $65M in CTCX stock and could gain up to $75M in potential milestone equity payments.
September 12, 2023 | 4:47 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Carmell Therapeutics (CTCX) is merging with Axolotl. Axolotl's shareholders will receive $65M in CTCX stock, with potential for an additional $75M in milestone equity payments.
The merger between Carmell Therapeutics and Axolotl could potentially impact CTCX's stock price. The distribution of $65M in CTCX stock to Axolotl's shareholders could lead to increased trading volume. However, the direction of the price movement will depend on the market's perception of the merger's value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100